Axsome Therapeutics
AXSM
231 hedge funds and large institutions have $2.61B invested in Axsome Therapeutics in 2023 Q2 according to their latest regulatory filings, with 50 funds opening new positions, 90 increasing their positions, 54 reducing their positions, and 16 closing their positions.
213% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 16
75% more call options, than puts
Call options by funds: $106M | Put options by funds: $60.5M
67% more repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 54
33% more capital invested
Capital invested by funds: $1.97B → $2.61B (+$647M)
17% more funds holding
Funds holding: 197 → 231 (+34)
4.83% more ownership
Funds ownership: 73.31% → 78.14% (+4.8%)
11% less funds holding in top 10
Funds holding in top 10: 9 → 8 (-1)
Top Buyers
Top Sellers
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$51.8M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$44.7M |
| 3 |
Holocene Advisors
New York
|
-$32.6M |
| 4 |
Millennium Management
New York
|
-$22.4M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$9.66M |
AXSM Hedge Fund Activity: Q2 2023 in Review
231 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q2 2023, worth a combined $2.61B — up 33% from $1.97B a quarter earlier.
Buyers outnumbered sellers: 50 funds opened new AXSM positions and 16 closed out — a net gain of 34 holders — while 90 added to existing stakes and 54 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $73.8M. The largest seller was Point72 Asset Management, cutting an estimated $51.8M.
- 231 institutional investors held Axsome Therapeutics (AXSM) as of Q2 2023, up from 197 in Q1 2023.
- Funds reported $2.61B of Axsome Therapeutics stock for Q2 2023, up 33% quarter-over-quarter.
- 50 funds opened new Axsome Therapeutics positions in Q2 2023 and 16 closed out, a net change of +34 holders.
- The largest Axsome Therapeutics buyer in Q2 2023 was RA Capital Management, an estimated $73.8M added.
- The largest Axsome Therapeutics seller in Q2 2023 was Point72 Asset Management, an estimated $51.8M sold.
Based on aggregated 13F filings for Q2 2023.